Plain-English translation of NCT07041268 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing —a medication that modifies the immune system—combined with standard insulin therapy in teenagers who were diagnosed with type 1 diabetes within the last few months. Half of the participants will receive repeated doses of plus insulin, while the other half will receive insulin alone. The goal is to see whether this new treatment approach can help preserve the body's ability to produce its own insulin longer than insulin therapy by itself.
Type 1 diabetes happens when the immune system mistakenly attacks the cells in the pancreas that make insulin. Researchers believe that calming down this immune attack early on—right after diagnosis—might help preserve the patient's remaining insulin-producing ability and make diabetes easier to manage over time.
You likely qualify if…
You likely don't qualify if…
If assigned to the group, you would visit the clinical center 13 times over one year to receive intravenous infusions of the medication and undergo physical exams and blood work. If assigned to the insulin-only group, you would visit 5 times over the year for check-ups and testing. Both groups will have their blood checked multiple times to measure how much insulin your pancreas is still producing. The study continues for an additional year if your body keeps making some insulin.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Russia